Literature DB >> 2134017

Oral vaccination using recombinant bacteria.

F Schödel1.   

Abstract

With the development of avirulent but immunogenic Salmonella strains it has become possible to deliver heterologous antigens to the mucosal and systemic immune system by the oral route. The basis of attenuation of different Salmonella mutants and the immune response to foreign antigens expressed by recombinant strains is discussed, as are problems related to the stabilisation of foreign genes in Salmonella and to the expression of immunogenic antigens.

Mesh:

Substances:

Year:  1990        PMID: 2134017

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  5 in total

Review 1.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

2.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

3.  Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits.

Authors:  I E Corthésy-Theulaz; S Hopkins; D Bachmann; P F Saldinger; N Porta; R Haas; Y Zheng-Xin; T Meyer; H Bouzourène; A L Blum; J P Kraehenbuhl
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

4.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 5.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.